ArticleBiomarker research2026
Impact of SARS-CoV-2 vaccination on cancer trends: a nationwide interrupted time series study.
Article in Biomarker research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundA recent population-based cohort study of Seoul residents in South Korea reported increased incidence of several cancers within one year of SARS-CoV-2 vaccination. We examined whether a short-term, population-level change in cancer incidence trends was detectable at the national vaccination rollout, using a design that does not compare vaccinated with unvaccinated individuals.
methodsWe conducted an interrupted time series analysis of Korea National Health Insurance Service data for 36,024,394 individuals born between 1955 and 2004, covering February 2011 to September 2025 (176 months). The intervention point was August 2021, when cumulative first-dose coverage exceeded 50%. Monthly incidence of 13 cancer categories defined by ICD-10 code ranges and of four site-specific cancers (stomach, colorectum, lung and prostate) was compared with counterfactual forecasts from ARIMA/SARIMA models, and segmented regression estimated immediate level and trend changes (significance threshold P < 0.01). The placement of the intervention point was varied from 0 to 18 months, and the resulting estimates were compared with those obtained at 30 placebo points in the pre-pandemic period.
resultsOverall, 89.3% of the population received at least one dose. No immediate level change (relative risk 0.923-1.072) or trend change (0.995-1.005) reached significance for any of the 13 categories, and none reached significance for the four site-specific cancers. Across the lag grid, 2.0% of estimates met the threshold, compared with 4.1% at placebo points. The 99% confidence limits excluded immediate increases larger than 8.9% to 23.0% across the 13 categories and 8.1% to 23.4% across the four site-specific cancers.
conclusionsThe national SARS-CoV-2 vaccination rollout in South Korea was not accompanied by a detectable short-term, population-level change in cancer incidence trends over the 50 months that followed.
trial registrationNot applicable.
Indexed as
Identifiers
42919412What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.